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Status of Drug Resistance in Tuberculosis 
after the Introduction of Rifampicin in lndia 
, 
The current threat in tuberculosis treatment lies on the fact of emergence of strains resistant to two most antituberculous drugs, 
isoniazid and rifampicin. Drug resistance to TB may be classified as primary and acquired. Causes of drug resistance are inefficient 
administration of effective treatment, poor case handling, use of sub-standad drugs, ignorance of healthcare workers, etc. Multi- 
drug resistant TB (MDR-TB) prevalence (median) in new case is highest (14.1%) in Estonia. Studies undertaken in different 
regions in India by Tuberculosis Research Centre (TRC) during 1997-2000 revealed acquired MDR-TB resistance levels of 25- 
100%. The key to successful prevention of  the emergence of drug resistance remains adequate case finding, prompt and correct 
diagnosis and effective treatment of infective patients. 
Key words : Drug resistance, multidrug resistant tuberculosis (MDR-TB), prevalence. 
espite all the advances in the treatment of tuberculosis (TB), this disease continues to be one of the D main public health problems facing mankind in the developing countries, with India accounting for 
nearly 30% of the global burden. 
Although drug-resistant M tuberculosis was observed even in the early days of chemotherapy 50 years 
ago, the current threat is due to the emergence of strains resistant to the two most potent antiTB drugs, 
namely isoniazid (H) and rifampicin (R) ie, multidrug resistant TB (MDR-TB). The level of initial drug 
resistance (DR) is an epidemiological indicator to assess the success of a national TB programme. Since 
current DR data has a bearing on the design of the treatment regimens and policies, reliable DR information 
is needed at national levels. 
DR in TB may be broadly classified as primary and acquired. DR in a patient who has never received 
anti-TB treatment previously is termed as primary resistance. Acquired resistance is that which occurs as 
a result of specific previous treatment. The term initial resistance is used to indicate primary resistance and 
resistance among patients whose history of previous chemotherapy is not known. The WHO and the 
IUATLD have replaced the term primary resistance by the term “drug resistance among new cases” and 
acquired resistance by the term “drug resistance among previously treated cases”1. 
Emergence of DR in TB patients results from a deficient or deteriorating TB control programme. Factors 
include inadequate or inefficient administration of effective treatment, poor case holding, use of sub- 
standard drugs, inadequate or irregular drug supply, ignorance of healthcare workers of the treatment and 
control of TB, and many others, 
The conventional methods of isolation, identification and indirect drug susceptibility testing of M 
tuberculosis usually require 8-10 weeks. In recent years, several new methods have been reported for 
reducing the time interval between specimen collection and receipt of results to 3 weeks or less. However, 
these methods require considerable technical expertise and are 
Council not financially viable for routine use in the disease endemic low 
income nations. 
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Based on the WHO/IUAT'LD Guidelines,2 a global DR surveillance project was conducted during 1994- 
99 in 65 countries, which report 28% of global cases.1 The median value for resistance to any drug among 
newcases was 11%(range 1.7%-41%7,and highest in H at 7% (range 0.0%-31.7%).The median prevalence 
of MDR-TB in new cases was 1% (range 0.0%- 14.1 %),with the highest prevalence reponed from Estonia 
(14.1%). Among previously treated cases, median prevalence of resistance to any drug was 33.4% with 
MDR-TB of 9.3% [range 0% to 48.2% (Iran)]. 
In order to monitor national treatment policy, reliable and periodic updates on the prevalence of DR for 
the entire country are needed, which would serve as an indication of the transmission of drug resistant 
organisms, as well as the erficacy of the TB control programme. However due to obvious reasons (country 
size, financial constraints, etc) .  surveys of DR at a national level in India are difficult to undertake. Most of 
the published reports on DR, with the exception of those from the Tuberculosis Research Centre (TRC) in 
Chennai and the National Tuberculosis Institute (NTI) in Bangalore, are deficient in varying technical 
aspects, such as methodology, proper elicitation of previous treatment history, sample selection, uniformity 
in bacteriological procedures, etc.3 
Table 1 - Summary of Studies on Initial Drug Resistance among M tuberculosis Isolates in India 
Location Period No of Any resistance (%) to 
isolates S H R SH HR 
During the l980s, though the levels of initial DR to H and streptomycin (S) were similar to those in the 
earlier studies the 1960s* 
resistance was observed in all the 
centres studied, except Gujarat (Table 
The reason for this was the Bangalore 
Wardha 
Gujarat 
Bangalore 
North Arcot 
Pondicherry 
Kolar 
Raichur 
Jaipur 
New Delhi 
Military Hospital, 
Military Hospital. 
Tamil Nadu State 
1980's 
1982-89 
1983-86 
1985-86 
1985-89 
1985-91 
1987-89 
1988-89 
1989-91 
1990.91 
Pune 1992-93 
Pune 1995-99 
1997 
436 5.7 17.4 3.0 3.9 1.1 
323 14.9 21.4 8.0 8.0 5.3 
570 7.4 13.8 0.0 4.2 0.0 
588 4.8 17.3 2.9 3.0 1.4 
2719 11.6 21.3 1.7 8.0 1.6 
1841 8.1 10.8 1.0 3.7 0.8 
292 5 . 1  32.9 4.4 4.1 3.4 
244 11.4 19.3 3.3 6.6 3.3 
324 ND 18.5 0.6 ND 0.6 
413 8.2 3.2 4.0 2.1 1.0 
1120 11.4 10.7 - - 3.7 
384 6.8 15.4 4.4 4.4 3.4 
1009 7.6 10.1 3.0 1.7 0.9 
introduction of R-containing short 
course chemotherapy (SCC) regimens 
during this period. However MDR-TB 
was <5% in all centres.In the I990s.a 
New Delhi study showed a high level 
of initial DR to H (18.5%) but low level 
of R resistance.3 Studies undertaken 
bytheTRCin the late 80s.during 1997- 
99 and 1999-2000, revealed initial 
resistance to ranging from 1.0-4.4%, 
with in MDR-TB prevalencence of 
between 1-3%4-6, 
North Arcot 1999 282 12.4 23.4 2.8 8.5 2.8 
1999 278 7.2 18.7 2.5 4.0 2.5 
Data on DR from almost 3,500 patients admitted to controlled clinical trials on R-containing SCC regimens 
conducted at TRC over the last 3 decades showed that H resistance rates ranged from 10-16% and for S 
from 8-13%. R resistance started appearing in 1990s and remains at around1%. with MDR-TB levels of 1% 
or less. These figures are considered to represent an accurate picture of true primary resistance in view of 
the detailed and repeated questioning methods used for eliciting history of previous treatment from the 
patients who were enrolled in the trials. 
Studies on acquired resistance from Gujarat (1980-86) showed an increase in resistance to H and R. and 
MDR-TB rates of 30%.3 A single time-point cross-sectional survey carried out by TRC on a cohort of 3357 
smear-positive patients in North Arcot found 67% acquired DR to H. 12% to R and 11% MDR-TB.7 A New 
Delhi study in the 1990s also showed high levels of acquired MDR-TB. A study conducted by the Institute 
of Thoracic Medicine, Chennai in 4 District TB Centres of Tamil Nadu. showed overall acquired resistance 
levels of 63%, with 20.3% MDR-TB.3 
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Studies undertaken in different regions of India by TRC during 1997-2000, revealed acquired MDR-TB 
resistance levels of 25-100%.5,6 However as these studies were not designed to obtain true levels of 
acquired resistance and data are based on small patient numbers, the results should be interpreted with 
caution. 
An ongoing study in 8 sites, with INCLEN funding, is expected to yield further data on the magnitude 
of drug resistant TB in India. Another ongoing study being undertaken by TRC in the Model DOTS area in 
Tiruvellore district is expected to reveal several aspects of disease dynamics and a precise estimate of initial 
and acquired DR. 
In view of the results presented above, there is no clear evidence of an increase in India of the prevalence 
of initial DR in the post-refampicin era. The prevalence of MDR-TB is also found to be at low levels in most 
regions of India. However, relatively high prevalence of acquired resistance has been reported from most 
regions. 
The key to successful prevention of the emergence of drug resistance remains adequate case finding, 
prompt and correct diagnosis, and effective treatment of infective patients. Directly observed therapy is a 
critical component of preventing the emergence of DR since it helps to ensure that patients take a full 
course of treatment. There is also a need for on-going DR surveillance in different regions by several 
investigators employing a common protocol, with DR levels serving as useful evaluation parameters of 
current and past TB chemotherapy programmes. 
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electronic connectivity with implementing districts, assuring smooth drug logistics, submitting two successful 
Global Fund Against AIDS, TB and Malaria(GFATM) proposals, receiving Global Drug Facility support 
and soliciting additional donor support for DOTS expansion activities. Additionally, RNTCP has recently 
published its operations research agenda and made strides in implementing the national HIV/TB action 
plan in higher prevalence states. 
RNTCP has accomplished a great deal over the past few years. This has been achieved through a 
collaborative effort that ranges from the individual patient in the most remote community to the international 
level. However, great challenges lie ahead for the programme and a collective effort will be needed to ensure 
that RNTCP prevails in its ambitious goal to control TB in India5. 
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